Quest Says It's Not Infringing Myriad's Gene Patents

Law360, Los Angeles (October 11, 2013, 4:36 PM EDT) -- Quest Diagnostics Inc. hit Myriad Genetics Inc. with a lawsuit in California federal court on Thursday, seeking a declaration that Quest does not directly or indirectly infringe a number of Myriad’s patents, including those protecting genes associated with an increased risk of breast cancer.

Quest says Myriad has threatened a patent infringement suit against any company that makes, uses, sells or offers to sell genetic tests and related services that use sequencing and analysis of BRCA1 and BRCA2 genes, which encode specific proteins responsible for repairing...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.